Investigational drug · Phase 2
and Carboplatin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non Squamous Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 30, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3,864
Any phase or sponsor naming "and Carboplatin"
First trial start
2023
Aug 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "and Carboplatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "and Carboplatin" as an intervention, largest first.
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
PfizerPfizer (PFE)
NCT05834348 · 5,279 participants · Start Jun 23, 2023 · Primary completion Jan 23, 2024
Drug: lorlatinib; crizotinib and 16 more · For: Non-Small Cell Lung Cancer
Sites: Oslo, Norway
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00011986 · 4,312 participants · Start Jan 2001 · Primary completion Mar 2010
Drug: Paclitaxel; Carboplatin and 3 more · For: Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Sites: Philadelphia, Pennsylvania
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
NCT00276640 · 3,417 participants · Start Apr 1, 2004 · Primary completion Dec 31, 2015
Drug: vincristine, carboplatin; vincristine, carboplatin, etoposide · For: Primary Central Nervous System Neoplasms
Sites: Vienna, Austria; Ghent, Belgium; Zagreb, Croatia · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Synthesis, characterization and in vitro cytotoxic activity of new Pt(II) complexes with trans-cinnamic acid.
Barbanente A, Di Cosola AM, Curlacci L, et al. · J Inorg Biochem 2027
- Anthracycline-Free Neoadjuvant Therapy With Nab-Paclitaxel and Carboplatin in Non-Luminal Breast Cancer: A Single-Arm Clinical Trial.
Wu J, Liu D, Chen M, et al. · Int J Cancer 2027
- A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.
Lambert C, Jamal R, Thébault P, et al. · Oncoimmunology 2026
- Metastatic Triple-Negative Male Breast Carcinoma of Occult Primary With Axillary Nodal and Cutaneous Metastases.
Sugiyama E, Di Lena E, Matsuda K, et al. · World J Oncol 2026
- Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-Analysis.
Rahim S, Kumari M, Abid E, et al. · Head Neck 2026
- Sintilimabߛrelated cystitis/ureteritis in highߛgrade endometrial stromal sarcoma: A case report and structured literature review.
Yang S, Gao R, Li D, et al. · Hum Vaccin Immunother 2026
Also in development for Non Squamous Non Small Cell Lung Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- MB12Proposed Pembrolizumab BiosimilarPhase 31 trial
mAbxience Research S.L. · Non Squamous Non Small Cell Lung Cancer
- IDP-001Phase 21 trial
InduPro, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.